Does UnitedHealthcare Cover Addyi (Flibanserin)?

What Is Addyi and Why Does Coverage Get Complicated?

Addyi (flibanserin 100 mg taken nightly) is the only FDA-approved non-hormonal medication for generalized acquired HSDD in premenopausal women. The FDA granted approval on August 18, 2015, after two earlier rejections, following data from the BEGONIA trial and companion studies showing statistically significant improvements in satisfying sexual events (SSEs) and desire scores versus placebo. [1][2]

Coverage disputes arise for several reasons. Addyi carries a boxed warning for hypotension and syncope when combined with alcohol or CYP3A4 inhibitors, which prompted the FDA to require a Risk Evaluation and Mitigation Strategy (REMS) program. [2] That REMS requires prescriber and pharmacy certification, adding administrative friction that some payers interpret as a reason to apply additional utilization management controls. Addyi is also a brand-only product with no FDA-approved generic as of January 2025, keeping its list price near $880 per month. [3]

UnitedHealthcare, like most large commercial insurers, uses formulary placement and prior authorization to manage high-cost brand drugs. The Women's Health and Cancer Rights Act and the ACA's preventive-care provisions do not compel coverage of HSDD medications, so Addyi coverage is subject to each plan's pharmacy benefit design. [4]

What Formulary Tier Is Addyi on UnitedHealthcare?

On most UnitedHealthcare commercial PPO and HMO plans, Addyi sits at Tier 3 (non-preferred brand). Tier 3 cost-sharing typically means a copay between $60 and $120 per 30-day supply after the deductible, though the exact amount varies by employer group and plan year. Some self-funded employer plans exclude Addyi from the formulary entirely, placing it in a "not covered" category that requires a formulary exception rather than a standard prior authorization.

Checking your specific plan is the right first step. UnitedHealthcare's online formulary search tool at myuhc.com allows real-time tier lookup by drug name and plan ID. If Addyi does not appear in the search results, ask the plan's pharmacy benefits manager whether the drug is excluded or simply not catalogued under that search term; flibanserin is the generic name and may return different results.

Plans that do list Addyi typically require prior authorization before dispensing. A 2022 analysis published in the Journal of Managed Care and Specialty Pharmacy found that brand-only CNS drugs with REMS programs faced prior authorization requirements on more than 78% of commercial formularies reviewed. [5] Addyi fits that profile exactly.

Prior Authorization Criteria for Addyi on UnitedHealthcare

UnitedHealthcare's prior authorization for Addyi generally requires the prescriber to document all of the following: a confirmed diagnosis of generalized acquired HSDD in a premenopausal woman (ICD-10 F52.0), evidence that the distress is not attributable to a relationship problem or another medical condition, absence of contraindicated medications including moderate-to-strong CYP3A4 inhibitors, and confirmation that the patient is not pregnant or planning to become pregnant during treatment. [2][6]

The prescriber must also be certified under the Addyi REMS. Prescriptions sent to a pharmacy that is not REMS-certified will not be filled regardless of insurance status, so verifying pharmacy eligibility before submitting the PA is worth doing at the outset.

The American College of Obstetricians and Gynecologists (ACOG) Practice Bulletin No. 213 states: "For premenopausal women with generalized acquired HSDD who have distress related to their sexual desire, flibanserin is an option after evaluation for and treatment of contributing medical and psychological factors." [6] Citing this guideline language in the PA request letter can strengthen the medical necessity argument.

Submitting a complete PA takes roughly 3 to 5 business days for standard review. Urgent reviews, available when a prescriber certifies clinical urgency, must be completed within 72 hours under federal managed care rules. [4]

Does UnitedHealthcare Require Step Therapy Before Approving Addyi?

Many UnitedHealthcare plans require documented step therapy before Addyi is approved. Step therapy for HSDD is conceptually different from step therapy for conditions with lower-cost generic alternatives, because no FDA-approved generic flibanserin exists. Instead, UHC may require documentation that the patient has attempted and failed or cannot tolerate non-pharmacologic approaches such as sex therapy, mindfulness-based cognitive behavioral therapy, or treatment of any identifiable contributing condition (e.g., depression managed with a non-libido-suppressing antidepressant).

The BEGONIA trial (N=949, published in the Journal of Sexual Medicine in 2014) compared flibanserin 100 mg nightly against placebo over 24 weeks in premenopausal women. The flibanserin arm showed a mean increase of 0.8 SSEs per 28 days versus 0.5 in the placebo arm (P<0.001), along with statistically significant improvements on the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO). [1] Framing step-therapy documentation around this level of clinical evidence, and showing that behavioral options were inadequate for a given patient, typically satisfies UHC reviewers.

The Women's Health Access Fairness Act, introduced in the 117th Congress and reintroduced in the 118th, would prohibit sex-based step therapy requirements in certain circumstances, but as of early 2025 it has not been enacted into federal law. [7] Thirteen states have passed step-therapy reform laws requiring exceptions for established therapies, but these apply only to state-regulated fully insured plans, not self-funded ERISA plans, which cover roughly 65% of privately insured Americans. [8]

How to Appeal a UnitedHealthcare Denial of Addyi

A denial is not necessarily final. UnitedHealthcare's standard appeals process runs two internal levels followed by an external Independent Review Organization (IRO) if the internal appeals fail.

Level 1 internal appeal. The prescriber or patient submits a written appeal with supporting clinical documentation within 180 days of the denial notice. Supporting materials should include the ACOG Practice Bulletin No. 213 recommendation, [6] the FDA label confirming Addyi's approved indication, [2] and the BEGONIA trial data showing clinical efficacy. [1] UHC must issue a decision within 30 days for pre-service appeals (60 days if the plan is non-urgent).

Level 2 internal appeal. If Level 1 fails, the patient requests a second review. UHC uses a different reviewer for Level 2. Turnaround is the same as Level 1.

External IRO review. After exhausting internal appeals, patients enrolled in fully insured plans regulated by state insurance departments can request external review under ACA provisions. The IRO's decision is binding on UHC. [4] Self-funded ERISA plan participants may need to pursue arbitration or federal litigation if the IRO route is unavailable.

A 2021 study in Health Affairs found that patients who submitted external appeals for specialty drug denials prevailed in approximately 39% of cases, a rate that justifies the effort. [9] Including a letter from the treating physician explaining why the denial causes patient-specific harm consistently improved outcomes in that cohort.

Expedited appeals, for urgent clinical situations, must be resolved within 72 hours. A prescriber's attestation that delay would seriously jeopardize the patient's health is required to trigger the expedited timeline. [4]

Cost and Savings Strategies If Coverage Is Denied or Partial

If UHC denies coverage or if the patient's cost-sharing leaves Addyi unaffordable, several options exist.

Manufacturer savings program. Sprout Pharmaceuticals, Addyi's manufacturer, offers a savings card program for commercially insured patients that may reduce out-of-pocket costs significantly. The card is not valid for patients covered by Medicare, Medicaid, or any other federal health care program due to anti-kickback statute restrictions. [3] Eligibility and savings amounts change periodically, so verifying current terms at addyi.com is advisable before counseling patients.

GoodRx and cash-pay pharmacies. GoodRx pricing for flibanserin 100 mg (30 tablets) varies by pharmacy but has ranged between $75 and $400 depending on location and available coupons. [10] This is meaningfully below the $880 list price.

Formulary exception request. If Addyi is excluded from the plan entirely, a formulary exception is a separate process from a PA appeal. The prescriber must show that all formulary alternatives are clinically contraindicated or have been tried and failed. Because no therapeutic equivalent exists for HSDD, this argument is medically straightforward, though administrative approval is not guaranteed.

Telehealth and specialty prescribers. Some telehealth platforms specializing in women's sexual health have established relationships with compounding pharmacies and REMS-certified dispensing networks that offer flibanserin at lower cash prices. Access through those channels does not bypass REMS certification requirements; the prescriber and pharmacy must still be enrolled.

What the Clinical Evidence Says About Flibanserin Efficacy

Understanding the evidence base helps patients and prescribers make the case for coverage and set realistic expectations. Flibanserin's mechanism differs from phosphodiesterase inhibitors used in male sexual dysfunction. It acts as a serotonin 5-HT1A agonist and 5-HT2A antagonist, with secondary dopaminergic activity, targeting central desire pathways rather than vascular mechanisms. [11]

The FDA's 2015 approval was based on three Phase 3 trials totaling more than 2,400 participants. Across those trials, women taking flibanserin 100 mg nightly reported a mean increase of 0.5 to 1.0 additional SSEs per 28 days compared with placebo. [2] The BEGONIA trial (N=949) additionally demonstrated that flibanserin reduced distress scores on the FSDS-DAO by a mean of 10.9 points versus 8.9 points for placebo (P<0.01) at week 24. [1]

A 2016 meta-analysis in the Journal of Sexual Medicine (six trials, N=5,914) found a pooled standardized mean difference of 0.27 for SSEs and 0.31 for desire scores, characterizing the treatment effect as modest but statistically significant and clinically meaningful for a subset of patients. [12] Adverse effects occurring in more than 5% of participants in Phase 3 trials included somnolence (11.2%), dizziness (10.7%), nausea (10.4%), and fatigue (9.2%). [2]

A 2023 real-world pharmacovigilance analysis drawing on FDA Adverse Event Reporting System (FAERS) data found that the hypotension signal was concentrated in patients who co-ingested alcohol or fluconazole, consistent with the boxed warning, rather than distributed broadly across all users. [13] This finding may be cited in PA requests to contextualize the risk profile for patients who do not drink alcohol or take CYP3A4 inhibitors.

REMS Requirements That Affect Prescribing and Dispensing

The Addyi REMS is a shared system certification program. Individual prescribers do not need patient-specific enrollment; instead, prescribers must complete a brief online training and attest to awareness of the risks. Certified pharmacies must counsel patients before dispensing. [2]

Telehealth prescribers can participate in the REMS. Virtual visits satisfy the prescriber-patient encounter requirement as long as the prescriber can adequately assess the HSDD diagnosis and document absence of contraindications. The FDA has not issued guidance restricting REMS certification to in-person prescribers. [2]

Mail-order pharmacies used by UnitedHealthcare's pharmacy benefit manager, Optum Rx, must also be REMS-certified to dispense Addyi. Confirming Optum Rx's REMS status before submitting the PA avoids a separate dispensing barrier after approval is obtained.

UnitedHealthcare Medicare Advantage and Addyi

Standard Medicare Part D formularies generally do not cover Addyi because CMS considers HSDD medications to fall outside the mandatory coverage categories defined in 42 CFR 423.120. [14] UnitedHealthcare Medicare Advantage prescription drug plans follow this same exclusion in most cases. Patients on Medicare have limited appeal options for excluded drug categories and are typically directed to cash-pay or manufacturer assistance programs, neither of which are available for federal beneficiaries with the Sprout savings card.

Patients transitioning from commercial insurance to Medicare who were stable on flibanserin should discuss this coverage gap with their prescriber well before their Medicare effective date, allowing time to consider alternatives or budget for cash-pay costs.